Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.

Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.

Abstract: Crystalline form I and form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof. Also, a method for treating an inflammatory disease in a patient in need thereof, which includes administering to the patient a therapeutically effective amount of the crystalline form I or the crystalline form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl) pyrrolidine-2-carboxylic acid.

Abstract: Compounds of formula (I), or the pharmaceutically acceptable salts and/or the solvates thereof, wherein m, n, R1, R2, R3, R4, R5, L, Ar1 and Ar2 are as defined as disclosed, which are useful as inhibitors of METTL3 (N6-adenosine-methlytransferase subunit) activity, in particular for the treatment of proliferative diseases such as cancers.

Abstract: Crystalline form I and form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof. Also, a method for treating an inflammatory disease in a patient in need thereof, which includes administering to the patient a therapeutically effective amount of the crystalline form I or the crystalline form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl) pyrrolidine-2-carboxylic acid.

Abstract: Crystalline form I and form II of (2S,5R)-5-(2-chlorophenyl)-1-(T-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid and preparation processes thereof. Also, a method for treating an inflammatory disease in a patient in need thereof, which includes administering to the patient a therapeutically effective amount of the crystalline form I or the crystalline form II of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl) pyrrolidine-2-carboxylic acid.

Abstract: A process of manufacturing of (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid (1), including the preparation of (2S,5R)-methyl 5-(2-chlorophenyl)pyrrolidine-2-carboxylate hydrochloride (6·HCl) as an intermediate of synthesis: Also, the sodium salt of the (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid (1), and its use in a pharmaceutical composition including sodium the (2S,5R)-5-(2-chlorophenyl)-1-(2?-methoxy-[1,1?-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylate and a method for treating and/or preventing inflammation in a patient.

Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Abstract: The present invention is directed to novel compounds of formula (I) and their use in treating and/or preventing metabolic diseases.

Abstract: The present invention is directed to novel intermediates of the formula E: which are useful in the synthesis of agonists of g-protein coupled receptor 43 for treating and/or preventing metabolic diseases.

Abstract: The present invention is directed to a process for the preparation of aryl-carbonyl-pyrrolidine carboxylic acid derivative compounds which are useful in treating metabolic diseases, said process consisting of coupling a pyrrolidine ester compound with an aryl carboxylic acid derivative, followed by alkaline or acidic treatment, hydrogenolysis or treatment with a fluoride of the obtained intermediate, to afford novel aryl-carbonyl-pyrrolidine carboxylic acid derivative compounds.

Abstract: Methods for forming sustained release microspheres and the products produced thereby are provided. The microspheres have a smooth surface that includes a plurality of channel openings that are less than 1000 angstroms in diameter.

Abstract: Methods relating to the field of biochemistry and more specifically relating to microparticles for use in diagnostics, therapeutics, and research are provided.

Abstract: Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromolecule and polymer. Each microparticle allows aqueous fluids to enter and allows solubilized macromolecule and polymer to exit the microparticle and may be formulated to provide a sustained release of macromolecule and polymer from the interior of the microparticle when placed in an appropriate aqueous medium, such as under physiological conditions. Methods of production and methods of use for research, diagnostics and therapeutics are provided.

Abstract: Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromolecule and polymer. Each microparticle allows aqueous fluids to enter and allows solubilized macromolecule and polymer to exit the microparticle and may be formulated to provide a sustained release of macromolecule and polymer from the interior of the microparticle when placed in an appropriate aqueous medium, such as under physiological conditions. Methods of production and methods of use for research, diagnostics and therapeutics are provided.

Abstract: Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromolecule and polymer. Each microparticle allows aqueous fluids to enter and allows solubilized macromolecule and polymer to exit the microparticle and may be formulated to provide a sustained release of macromolecule and polymer from the interior of the microparticle when placed in an appropriate aqueous medium, such as under physiological conditions. Methods of production and methods of use for research, diagnostics and therapeutics are provided.